$857 Million is the total value of Third Rock Ventures, LLC's 6 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SAGE | New | Sage Therapeutics, Inc. | $367,952,000 | – | 11,681,008 | +100.0% | 42.92% | – |
| AGIO | Sell | Agios Pharmaceuticals, Inc. | $188,350,000 | +5.5% | 3,070,090 | -21.2% | 21.97% | -42.3% |
| ZFGN | New | Zafgen Inc. | $110,080,000 | – | 5,602,045 | +100.0% | 12.84% | – |
| FMI | Foundation Medicine, Inc. | $93,420,000 | -29.7% | 4,927,234 | 0.0% | 10.90% | -61.6% | |
| EBIO | Eleven Biotherapeutics, Inc. | $53,935,000 | -15.5% | 4,841,591 | 0.0% | 6.29% | -53.8% | |
| BLUE | Sell | bluebird bio, Inc. | $43,596,000 | -53.2% | 1,215,054 | -49.7% | 5.08% | -74.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-10-22
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ELEVEN BIOTHERAPEUTICS INC | 7 | Q3 2015 | 13.9% |
| Foundation Medicine, Inc. | 6 | Q1 2015 | 44.6% |
| SAGE THERAPEUTICS INC | 5 | Q3 2015 | 66.7% |
| Agios Pharmaceuticals, Inc. | 5 | Q4 2014 | 38.6% |
| bluebird bio, Inc. | 5 | Q4 2014 | 22.4% |
| ZAFGEN INC | 5 | Q3 2015 | 17.8% |
| BLUEPRINT MEDICINES CORP | 2 | Q3 2015 | 20.4% |
| GLOBAL BLOOD THERAPEUTICS IN | 1 | Q3 2015 | 58.1% |
View Third Rock Ventures, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2015-11-03 |
| 13F-HR | 2015-07-30 |
| 13F-HR | 2015-04-29 |
| 13F-HR | 2015-01-26 |
| 13F-HR | 2014-10-22 |
| 13F-HR | 2014-07-30 |
| 13F-HR | 2014-04-30 |
| 13F-HR | 2014-02-14 |
View Third Rock Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.